AstraZeneca PLC (AZN)

NASDAQ: AZN · IEX Real-Time Price · USD
67.75
-0.51 (-0.75%)
Mar 28, 2024, 4:00 PM EDT - Market closed
-0.75%
Market Cap 210.70B
Revenue (ttm) 45.81B
Net Income (ttm) 5.96B
Shares Out 3.10B
EPS (ttm) 1.91
PE Ratio 35.77
Forward PE 16.23
Dividend $1.45 (2.14%)
Ex-Dividend Date Feb 22, 2024
Volume 3,417,857
Open 68.18
Previous Close 68.26
Day's Range 67.68 - 68.36
52-Week Range 60.47 - 76.56
Beta 0.17
Analysts Buy
Price Target 81.67 (+20.55%)
Earnings Date Apr 25, 2024

About AZN

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]

Sector Healthcare
IPO Date May 12, 1993
Employees 89,900
Stock Exchange NASDAQ
Ticker Symbol AZN
Full Company Profile

Financial Performance

In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $81.67, which is an increase of 20.55% from the latest price.

Price Target
$81.67
(20.55% upside)
Analyst Consensus: Buy
Stock Forecasts

News

AstraZeneca CEO Soriot on Pharmaceuticals in China

AstraZeneca CEO Pascal Soriot discusses the drugmaker's business strategy in China, the US “BIOSECURE Act,” and future deals and partnerships in China. He speaks with Stephen Engle on the sidelines of...

1 day ago - Bloomberg Markets and Finance

AstraZeneca: Fusion acquisition will be a cost effective-investment that can improve cancer outcomes

Dr. Susan Galbraith, executive vice-president of oncology and R&D at AstraZeneca, discusses the healthcare giant's $2.4bn acquisition of Fusion Pharmaceuticals.

8 days ago - CNBC International TV

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation rad...

9 days ago - Business Wire

AstraZeneca to buy Fusion Pharmaceuticals for up to $2.4 billion

AstraZeneca is buying Fusion Pharmaceuticals for $2.4 billion as the London-listed group looks to build its presence in cutting-edge cancer treatments.

Other symbols: FUSN
9 days ago - Market Watch

AstraZeneca to buy Fusion Pharma for $2 billion in cash

AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash to boost its oncology portfolio.

Other symbols: FUSN
9 days ago - Reuters

AstraZeneca to cap US out-of-pocket costs for inhalers to $35

AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products for chronic lung disease and asthma to $35 per month, starting June, in the United States.

10 days ago - Reuters

AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month f...

10 days ago - Business Wire

AstraZeneca To Buy Amolyt Pharma for $1.05B To Expand Rare Disease Pipeline

AstraZeneca PLC (AZN) plans to acquire biotech firm Amolyt Pharma for $1.05 billion in cash, the drugmaker said Thursday, boosting its pipeline of drugs to treat rare diseases.

14 days ago - Investopedia

Sofinnova Partners Portfolio Company Amolyt Pharma to be Acquired by AstraZeneca

PARIS--(BUSINESS WIRE)-- #VC--Sofinnova Partners announced that its portfolio company, Amolyt Pharma, has entered into a definitive agreement with AstraZeneca for its acquisition.

14 days ago - Business Wire

AstraZeneca strikes $1 billion deal for rare-disease drug maker

AstraZeneca on Thursday struck a $1 billion deal to buy a maker of drug for rare diseases, further building out the capabilities it acquired in the 2021 deal for Alexion Pharmaceuticals.

14 days ago - Market Watch

Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca

AstraZeneca will acquire Amolyt Pharma for up to $1.05 billion in total consideration The transaction is expected to close in the third quarter of 2024 LYON, France and CAMBRIDGE, Mass., March 14, 202...

14 days ago - GlobeNewsWire

AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare diseases portfolio

Drugmaker AstraZeneca said on Thursday it will acquire rare endocrine diseases-focused firm Amolyt Pharma for $1.05 billion in cash, in a bid to boost its rare diseases portfolio.

14 days ago - Reuters

AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the initiation of a Phase III trial to investigate the potential effect of triple-combination inhaled therapy BREZTRI AEROSPHERE® (budeso...

15 days ago - Business Wire

Astra-Sanofi's RSV therapy 'highly effective' against infant hospitalizations, CDC study shows

AstraZeneca and Sanofi's antibody therapy was 90% effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV), a study by the U.S. Centers of Disease Contro...

Other symbols: SNY
21 days ago - Reuters

AstraZeneca Announed Further GBP200 Million Investment Announced to Expand Presence in Cambridge

The government also said AstraZeneca and the U.K. Health Security Agency plan to partner “to advance science for developing and evaluating vaccines.”

22 days ago - WSJ

AstraZeneca to invest 650 million pounds in UK to boost 'pandemic preparedness'

AstraZeneca plans to invest 650 million pounds ($826.80 million) in Britain to boost research, development and manufacturing of vaccines, the government announced on Wednesday as part of Finance Minis...

22 days ago - Reuters

Renewable Thermal Collaborative Releases Case Study on the U.S. Renewable Natural Gas (RNG) Agreement between AstraZeneca and Vanguard Renewables

BOSTON--(BUSINESS WIRE)--The Renewable Thermal Collaborative recently released a case study on the first-of-its-kind partnership between AstraZeneca and Vanguard Renewables to enable the delivery of r...

24 days ago - Business Wire

Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer

TOKYO & MUNICH--(BUSINESS WIRE)--The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN...

24 days ago - Business Wire

Judge rejects AstraZeneca's challenge to Medicare drug price negotiations

U.S. District Judge Colm Connolly's decision comes one day before manufacturers have to respond to Medicare's initial price offers for their drugs.

27 days ago - CNBC

‘GRANOLAS' vs. the Magnificent Seven: Which should you dig into now?

Wall Street loves a good story, as evidenced by the recent focus on a group of stocks called the “GRANOLAS.” These are a group of 11 European stocks that have led Europe's stock markets higher.

4 weeks ago - Market Watch

SCRI Announces a Collaboration with AstraZeneca Focused on Technology Enhancements & Innovative Operational Model to Advance Cancer Research

NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, announced today a coll...

4 weeks ago - Business Wire

FibroGen regains rights to anemia drug from AstraZeneca

FibroGen Inc said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca after the companies mutually agreed to terminate their collaboration agreement.

Other symbols: FGEN
4 weeks ago - Reuters

Sodexo and AstraZeneca extend their global partnership for a further 5 years.

Sodexo and AstraZeneca extend their global partnership for a further 5 years. Issy les Moulineaux, February 22, 2024 Sodexo reinforces its contract of Food and Facilities Management Services with Astr...

5 weeks ago - GlobeNewsWire

Positive lung cancer results show our strategy is working: AstraZeneca

Greg Rossi, senior vice president of oncology in Europe and Canada at AstraZeneca, discusses the company's three announcements on lung cancer drugs and treatments.

5 weeks ago - CNBC International TV

AstraZeneca's stock surges on FTSE 100 on Tagrisso approval

AstraZeneca's (LON: AZN) stock surged on the FTSE 100 index following the announcement of the approval of its lung-cancer drug Tagrisso, in combination with chemotherapy. AstraZaneca's shares were up ...

5 weeks ago - Invezz